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Abstract
Background: Stress fractures are a common and potentially debilitating overuse injury to bone and occur
frequently among military recruits and athletes. Recovery from a lower body stress fracture typically requires several
weeks of physical rehabilitation. Teriparatide, a recombinant form of the bioactive portion of parathyroid hormone
(1–34 amino acids), is used to treat osteoporosis, prevent osteoporotic fractures, and enhance fracture healing due
to its net anabolic effect on bone. The study aim is to investigate the effect of teriparatide on stress fracture healing
in young, otherwise healthy adults undergoing military training.
Methods: In a two-arm, parallel, prospective, randomised controlled, intention-to-treat trial, Army recruits (n = 136
men and women, 18–40 years) with a magnetic resonance imaging (MRI) diagnosed lower body stress fracture
(pelvic girdle, sacrum, coccyx, or lower limb) will be randomised to receive either usual Army standard care, or
teriparatide and usual Army standard care. Teriparatide will be self-administered by subcutaneous injections (20 μg/
day) for 16 weeks, continuing to 24 weeks where a fracture remains unhealed at week 16. The primary outcome will
be the improvement in radiological healing by two grades or more, or reduction to grade zero, 8 weeks after
randomisation, assessed using Fredericson grading of MRI by radiologists blind to the randomisation. Secondary
outcomes will be time to radiological healing, assessed by MRI at 8, 10, 12, 14, 16, 20 and 24 weeks, until healed;
time to clinical healing, assessed using a clinical severity score of injury signs and symptoms; time to discharge
from Army physical rehabilitation; pain, assessed by visual analogue scale; health-related quality of life, using the
Short Form (36) Health Survey; and adverse events. Exploratory outcomes will include blood and urine
biochemistry; bone density and morphology assessed using dual-energy X-ray absorptiometry, peripheral
quantitative computed tomography (pQCT), and high-resolution pQCT; physical activity measured using
accelerometers; and long-term future fracture rate.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: a.carswell@uea.ac.uk
1Norwich Medical School, Faculty of Medicine and Health Sciences,
University of East Anglia, Norwich NR4 7TJ, UK
Full list of author information is available at the end of the article
Carswell et al. Trials          (2021) 22:580 
https://doi.org/10.1186/s13063-021-05556-3
Discussion: This study will evaluate whether teriparatide, in addition to standard care, is more effective for stress
fracture healing than standard care alone in Army recruits who have sustained a lower body stress fracture.
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Introduction
Background and rationale {6a}
Stress fractures are a common and potentially debilitating
overuse injury to bone and are frequently reported among
military recruits and athletes [1–6]. Bone normally remodels
through a continual, balanced cycle of osteoclastic resorption
and osteoblastic bone formation. Sudden increases in
training volume of high-intensity, repetitive impact activities
(e.g. running and marching) without adequate time for re-
covery can cause an imbalance in bone remodelling [7], with
greater osteoclastic activity at the sites of mechanical loading
causing a weakening of the bone, microdamage, and a subse-
quent stress fracture [5, 8]. Stress fracture injuries can lead
to a full fracture without a significant reduction in physical
activity levels and a period of rehabilitation [9]. Lower body
(i.e. pelvic girdle, sacrum, coccyx, and lower limb) stress frac-
tures require the longest rehabilitation times of all musculo-
skeletal injuries sustained during Army Infantry training,
often exceeding 80 days [2]. The return to training of athletes
who have sustained lower body stress fractures takes
between 61 and 153 days, on average [6].
Daily subcutaneous injections of teriparatide, a
recombinant form of the bioactive portion of parathyroid
hormone, containing the first 34 amino acids, have been
used to treat osteoporosis, prevent osteoporotic fractures
and enhance fracture healing due to its net anabolic effect
on bone [10–12]. Continuous infusion of teriparatide has a
catabolic effect on bone, whereas intermittent daily
injections have an anabolic effect [13–17]. Accelerated bone
remodelling, earlier replacement of woven bone with
lamellar bone, and improvements in mechanical strength,
bone mineral content, and callus volume and strength have
been documented after the administration of teriparatide in
animal models of fracture healing (e.g. long bones of rat,
mouse, rabbit, monkey [10]). A number of studies
conducted in postmenopausal women and osteoporotic
patients have demonstrated increased bone mineral density
[18–21], bone mineral content [20–22], and an increase in
biochemical markers of bone formation and resorption [18,
19, 23] following treatment with teriparatide. Pain in limb
(reported by ≥ 10% of patients), followed by nausea,
headache, and dizziness (each reported by ≥ 1% to < 10% of
patients) are the most common adverse reactions to
teriparatide [24]; nevertheless, treatment with teriparatide in
humans is considered safe [24–26]. In randomised
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controlled trials, 8 weeks of daily teriparatide accelerated
fracture healing in postmenopausal women [27], and
parathyroid hormone [1-84] accelerated fracture
healing and reduced pain after 8 weeks, and improved
mobility in elderly osteoporotic women (aged > 70
years) [28]. No effect of teriparatide on fracture
healing or pain was observed in two randomised
controlled trials treating men and postmenopausal
women (aged ≥ 50 years) [29, 30], but the treatment
was limited to 4 weeks [29], and the trials were
underpowered [29, 30]. Randomised controlled trials
comparing teriparatide with bisphosphonates reported
increased bone mineral density and decreased fracture
risk with teriparatide use in postmenopausal osteoporosis
patients [31], but variable effects on radiological healing,
pain, and quality of life have been observed in men and
women [32, 33]. The assessment of different outcome
measures and inclusion of various fracture types might be
responsible for these variable responses to teriparatide
compared with bisphosphonates. Teriparatide reduced the
risk of future fractures compared with placebo in
postmenopausal women with prior fractures [20, 34], but
no studies have examined this effect in young adults.
Only one published randomised controlled pilot study
has examined the effect of teriparatide on stress fracture
healing in young adults (aged 21–45 years) [35]. Using
Fredericson grading of magnetic resonance imaging
(MRI) to assess the healing of lower limb fractures, four
women (67%) who received teriparatide for 8 weeks,
compared with three women (43%) in the placebo
control group, achieved a two grades or more
improvement in healing or reduction to grade zero.
Biochemical markers of bone formation increased more
in women who received teriparatide compared with
placebo [35], indicating a significant anabolic window,
whereby teriparatide initially stimulates bone formation,
with a rapid increase in bone formation markers during
the initial weeks, followed by increases in bone
resorption markers in later weeks [36]. A number of
case studies of young and elderly adults (32–91 years)
support the efficacy of teriparatide for accelerating
fracture [10] and stress fracture healing [37]. Despite
these encouraging findings, the effectiveness of
teriparatide for promoting fracture healing remains
unclear, particularly among young, otherwise healthy
adults. High quality randomised controlled trials are
required to test the efficacy of teriparatide for stress
fracture healing.
Optimising the healing of stress fractures is relevant to
the military training environment because quality of
healing, time to fracture union and return to training
can have significant consequences for military recruits in
terms of career progression, and risk of re-injury and
medical discharge, and the Ministry of Defence in terms
of the cost of working days lost in rehabilitation and loss
of recruits from training. Changes to initial military
training intended to reduce the risk of musculoskeletal
injury have mostly been ineffective [2]. Effective
strategies for optimising the rehabilitation of stress frac-
ture injuries and expediting a return to training will im-
prove the overall health and wellbeing of individuals and
may also reduce medical attrition rates. The aim of the
present study is to evaluate the effect of daily teripara-
tide injections on lower body stress fracture healing in
young, otherwise healthy adults undergoing Army
training.
Objectives {7}
The primary objective of the RETURN trial is to
investigate the effect of teriparatide in addition to usual
Army standard care on lower body stress fracture
healing in military recruits, compared with usual Army
standard care alone. The primary outcome will be the
improvement in radiological healing, assessed using
Fredericson grading of MRI, by two grades or more, or
reduction to grade zero, 8 weeks after randomisation.
Secondary objectives are to examine the effect of
teriparatide on (i) time to radiological healing; (ii) time
to clinical healing, assessed by clinical severity score
calculated from injury signs and symptoms; (iii) time to
discharge from Army physical rehabilitation; (iv) pain
symptoms; (v) health-related quality of life; and (vi) ad-
verse events. It is hypothesised that treatment with teri-
paratide will accelerate (i) the rate of radiological healing
of lower body stress fractures; (ii) the cessation of pain
associated with the injury; and reduce (iii) the time taken
to return to Army training, compared with standard care
alone. The effect of teriparatide on the following ex-
ploratory outcomes will also be investigated: (i) blood
and urine biochemistry; (ii) bone density and morph-
ology; (iii) physical activity levels; and (iv) long-term fu-
ture fracture rate.
Trial design {8}
The RETURN trial is a phase III, multicentre, open
label, two-arm parallel, prospective, randomised con-
trolled trial (Fig. 1). A 1:1 allocation ratio will be used in
this intention-to-treat, superiority trial.
Methods: Participants, interventions and
outcomes
Study setting {9}
The study will take place in the UK, at the Infantry
Training Centre, Catterick, North Yorkshire and a
nearby National Health Service (NHS) institution within
the County Durham and Darlington NHS Foundation
Trust, neither of which are part of the University of East
Anglia.
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Fig. 1 (See legend on next page.)
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Eligibility criteria {10}
Men and women, aged 18–40 years, with single or
multiple lower body stress fractures, diagnosed by MRI a
maximum of 7 days before date of consent, will be eligible
to participate. Potential participants must be undergoing
Phase One or Two Army training (i.e. initial or trade
training) and will, therefore, have recently passed a
physician-screened medical assessment. Eligible partici-
pants must provide written informed consent and be able
to comply with the study protocol, adhere to study visit
requirements, and have baseline safety blood test results
within adult reference ranges (analytes listed in Table 1).
Potential participants will be excluded if they have any
of the following: known hypersensitivity to active
parathyroid hormone or any excipients listed in the
summary of product characteristics [24]; pre-existing
hypercalcaemia; a history of skeletal malignancies or
bone metastases; any contraindications that would pre-
vent them from undergoing an MRI scan; severe renal
impairment (participants with a moderate renal impair-
ment will be treated with caution at the Principal Inves-
tigator’s discretion and in accordance with the summary
of product characteristics [24]); metabolic bone diseases,
including a pre-existing diagnosis of hyperparathyroid-
ism or Paget’s disease of bone; an unexplained elevation
of alkaline phosphatase; prior external beam or implant
radiation therapy to the skeleton; depression, identified
by the Columbia-Suicide Severity Rating Scale (C-SSRS);
or are receiving digoxin or any other concurrent therapy
that would interfere with the evaluation of the safety or
efficacy of teriparatide; currently pregnant, suspect they
are pregnant, or are breastfeeding; present with open
(See figure on previous page.)
Fig. 1 Overview of the trial design, interventions and assessments. 1Serum 25-hydroxyvitamin D < 30 nmol/L, deficient; ≥30 nmol/L, not deficient;
2Pregnancy test for all at baseline, week 16 and 24, and four-weekly for participants allocated to the intervention arm; 3Weekly visual analogue
scale; 4Short Form (36) Health Survey; 5Dual-energy X-ray absorptiometry (DXA) scan of the lumbar spine and hips (baseline and week 16 only);
peripheral quantitative computed tomography (pQCT) scan of the diaphyseal tibia; and high-resolution pQCT (HR-pQCT) scan of the metaphyseal
tibia and radius; 6Accelerometer worn 24 h/day and replaced four-weekly; 7Columbia-Suicide Severity Rating Scale (C-SSRS) for all at baseline, and
four-weekly for participants allocated to the intervention arm; 8Review of Army fitness records; 9Magnetic resonance imaging (MRI) scans to cease
when fracture is radiologically healed; 10Clinical assessments twice weekly after fracture is radiologically healed, and to cease when fracture is
clinically healed; 11Review of Army medical records
Table 1 Blood and urine biochemistry
Baseline only Baseline and weeks 4, 8, 12, 16, 20 and 24
Blood Safety Haemoglobin
Platelets
















High- and low-density lipoproteins
Total cholesterol





Procollagen type 1 N-terminal propeptide
Sclerostin
Osteoprotegerin
Receptor activator of nuclear factor kappa-B ligand
Dickkopf-related protein 1








Additional bone remodelling compounds may be analysed if assay methodologies are validated during the trial
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epiphyses in their diagnostic MRI scan; or are participat-
ing in a concurrent drug trial. Potential participants will
be excluded if they are in receipt of an investigational
drug or biological agent within the 4-week period prior
to study entry (or five times the half-life if this is longer).
Participants can be entered into other observational
studies given prior agreement from the Trial Manage-
ment Groups (TMGs) of both studies. Women must
have a negative serum pregnancy test at baseline and
agree to use a highly effective form of contraception
(with a failure rate < 1% per year) for the duration of
their participation in the study.
Principal Investigators (or medically trained delegates)
will be appropriately qualified and licensed to practice
within their trial site. Suitably trained staff will
undertake delegated trial activities. All investigators will
sign an investigator statement to confirm they will
comply with the study protocol. Sites responsible for
prescribing and dispensing drugs will have a pharmacy
that is able to store, prepare and dispense drugs
appropriately.
Who will take informed consent? {26a}
Written informed consent will be obtained by an
appropriately trained clinician or delegated member of
staff at the NHS institution in person, or remotely
(consent form completed by the participant during a
telephone or video call) if NHS hospital visits are
restricted for any reason. Potential participants will be
provided with a participant information sheet and will
be invited to meet investigators for a detailed
explanation of the study’s aims, methods, benefits and
potential hazards. Consent will be obtained a minimum
of 24 h after the potential participant receives the
participant information sheet and detailed explanation of
the study; and a maximum of 7 days after their diagnosis
with a lower body stress fracture using MRI. Consent
will be obtained in the absence of the participants’ Army
Chain of Command, and it will be explained to potential
participants that choosing to take part, or not, or
choosing to withdraw from the study at any point, will
have no bearing on their future Army training or career.
Potential participants who wish to take part will provide
informed consent before any trial-specific procedures
are undertaken. Participants will be invited to provide
additional consent to wear an accelerometer for the dur-
ation of their participation in the study, however, this is
optional, and participants may refuse whilst remaining
eligible to take part.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Participants will be asked to consent to their samples
being stored securely in a pseudoanonymised form for
use in future studies, pending ethical approval. No
ancillary studies are planned.
Interventions
Explanation for the choice of comparators {6b}
There are no current pharmacological therapies
indicated for the treatment of stress fractures. The
control arm will receive usual Army standard care.
Participants will commence a period of physical
rehabilitation under the supervision of a physiotherapist
and Army exercise rehabilitation instructor, in
accordance with standard Army procedures. The
intervention arm will receive 20 μg/day of teriparatide by
subcutaneous injection in addition to usual Army
standard care. This is the only licensed dose for
teriparatide in Europe. Teriparatide is licensed for the
treatment of osteoporosis in postmenopausal women
and in men at increased risk of fracture, and the
treatment of osteoporosis associated with sustained
systemic glucocorticoid therapy in women and men at
increased risk for fracture [24]. An open label design
was chosen for a number of reasons: (i) the aims of the
study and objective primary endpoint indicated an open
label design; (ii) it was not possible to procure a
matched placebo; (iii) there will be no requirement for
control arm participants to administer themselves with
daily injections of placebo for up to 24 weeks, thereby
reducing the burden on them, and avoiding the possible
ethical implications of requiring them to do so; and (iv)
adherence to the injection regime may be improved with
intervention arm participants knowing they are receiving
active drug. The practical issue of adherence to the
injection regime by military recruits, knowing they are
receiving the drug, is of importance to the Ministry of
Defence and the future roll-out of any treatment regime.
Intervention description {11a}
All participants will receive usual Army standard care.
According to standard Army procedures, all recruits will
be taken out of training on confirmation of their injury
and referred for extended rehabilitation in a
rehabilitation platoon. Recruits may be sent on sick
leave, with the duration determined according to the
severity of their injury and symptoms. Early
rehabilitation will concentrate on upper body, non-
impact cardiovascular work and swimming/deep water
running. Exercise interventions will aim to maintain car-
diovascular fitness using non-impact activities and to
maintain strength as pain allows. Once rehabilitation is
complete and a recruit is fully fit, they will be graded as
fit to return to training. The final functional test before
a decision to return to training is made will be the suc-
cessful completion of a weighted distance march without
symptoms, at a level appropriate to the week of training
Carswell et al. Trials          (2021) 22:580 Page 6 of 18
they are returning to. A review by an Army exercise re-
habilitation instructor, physiotherapist and general prac-
titioner will be required to determine if a recruit is ready
to return to training. The rehabilitation team will be in-
formed of a recruit’s participation in the study, but this
will not affect their treatment or rehabilitation
programme in any way.
Participants randomly allocated to the intervention
arm will receive teriparatide (Terrosa, Gedeon Richter,
Budapest, Hungary) in addition to usual Army standard
care. Daily subcutaneous injections of teriparatide
(20 μg) will be self-administered into the abdomen or
thigh using an injection pen and sterile, single use nee-
dles. Cartridges of 2.4 mL of a solution containing
600 μg of teriparatide (250 μg/mL) will provide 28 indi-
vidual fixed doses of 20 μg of teriparatide (20 μg/80 μL
solution) when used with a bespoke injection pen. A
sharps bin will be provided for the disposal of used nee-
dles. Participants will be instructed to store their teri-
paratide cartridge and injection pen in a refrigerator
(2–8 °C). Doses will be reconciled, and a replacement
cartridge will be dispensed by the NHS pharmacy every
4 weeks. Daily teriparatide injections will be self-
administered for 16 weeks, but where a fracture re-
mains unhealed at week 16, daily injections will con-
tinue until week 24. Participants will be given a user
manual that fully describes how to use the injection
pen and will be trained to use the proper injection
technique by investigators. Participants will be
instructed to inject at the same time every day. If they
forget to inject or are unable to inject at their usual
time, participants may take their dose up to 12 h later
than planned. When participants are onsite at Infantry
Training Centre, Catterick, their teriparatide cartridge
and injection pen will be stored by investigators in a
temperature monitored refrigerator. When participants
are at home there will be no formal temperature moni-
toring. Participants will be provided with a travel cool
pack to transport their teriparatide cartridge and injec-
tion pen when travelling between locations.
Participants identified with vitamin D deficiency
(serum 25-hydroxyvitamin D < 30 nmol/L [38]) will be
treated in accordance with the Ministry of Defence
regulation JSP 950, Part 1, Leaflet 2-9-3, irrespective
of which arm they have been allocated to. Under the
terms of this regulation, to manage vitamin D defi-
ciency, a daily dose of 3200 IU cholecalciferol using
cholecalciferol 800 IU (Fultium D3/Desunin), or a
weekly dose of 60,000 IU (or 20,000 IU on alternate
days) using cholecalciferol 20,000 IU capsules will lead
to restoration of body stores over 8 to 12 weeks.
Long-term maintenance/supplementary therapy is
then needed with the equivalent of cholecalciferol
1000 or 2000 IU daily or 10,000 IU weekly.
Criteria for discontinuing or modifying allocated
interventions {11b}
Participants may stop their treatment with teriparatide
at any time if they wish. For safety reasons, treatment
will be discontinued for individual participants if they
experience an unacceptable adverse event or treatment
toxicity; an intercurrent illness that prevents further
treatment; any change in their condition that in the
clinician’s opinion justifies ceasing treatment; or any
contraindication to continuing treatment within the
summary of product characteristics, including pregnancy
[24]. Participants who have their treatment interrupted
for 2 weeks or more, intentionally overdose, or exhibit
signs of depression (indicated by the C-SSRS completed
every 4 weeks prior to teriparatide re-dispensing) will
also have their treatment discontinued. Discontinuation
of treatment with teriparatide will not be a reason for
withdrawal from the study, and participants will
complete follow-up visits provided they are willing.
Where pre-dose serum calcium is found to be above the
upper limit of normal, treatment will be withheld until
serum calcium returns to normal and restarted every
other day, or every third day according to the clinical
judgement of the treating clinician and Chief Investiga-
tor. Before restarting treatment, the participant’s correct
use of the injection pen will be verified, and differential
diagnoses will have been excluded (e.g. primary hyper-
parathyroidism, excess vitamin D and malignancy).
Where pre-dose serum calcium is < 2 mmol/L, treatment
will continue with the addition of twice daily calcium
(1500 mg) and vitamin D (400 IU) supplementation.
Strategies to improve adherence to interventions {11c}
Face-to-face reminders about how and when to inject
teriparatide, how to store teriparatide, and what to do in
the event of a missed dose will take place when the drug
is initially dispensed, each time the drug is re-dispensed,
and during each study visit. Participants will record self-
administration of teriparatide in a daily diary. Diaries
will be reviewed by investigators every 4 weeks, alongside
any problems that participants might be having with in-
jections, and the reasons for any missed doses. Used teri-
paratide cartridges will be collected from participants
every 4 weeks, with the number of unused doses re-
corded to monitor adherence to the intervention.
Relevant concomitant care permitted or prohibited
during the trial {11d}
The use of medication bought over the counter or
prescribed by other healthcare professionals will be
permitted, except for non-steroidal anti-inflammatory
drugs and vitamin D or its analogues. Participants’ use
of analgesics will be recorded throughout the study
using their participant diary. The combined use of
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teriparatide and cardiac glycosides (e.g. digoxin or digi-
toxin) may predispose participants to digitalis toxicity
[24]; thus, participants required to begin taking cardiac
glycosides will be withdrawn from the study. Participants
required to begin taking medications that affect serum
calcium (including but not limited to lithium, thiazides
or alendronic acid) will also be withdrawn from the
study.
Provisions for post-trial care {30}
There will be no provisions for post-trial care, including
continuation of treatment with teriparatide. Teriparatide
is not currently licensed for the treatment of stress frac-
tures and cannot be prescribed outside of the trial. The
Ministry of Defence maintains an arrangement for the
payment of no-fault compensation to individuals who
suffer illness, injury or death as a direct result of partici-
pating as a volunteer in research conducted on their be-
half and given favourable opinion by the Ministry of
Defence Research Ethics Committee (MODREC). As a
trial sponsored by an NHS organisation, NHS insurance
for negligent harm covers sponsor activities and those of
participating NHS trusts. Non-negligent harm does not
include side effects, which are listed in the trial protocol
and participant information sheet. Under the terms of
the no-fault compensation scheme, the Ministry of De-
fence insures against side effects that are listed in the
trial protocol and participant information sheet, as well
as unknown side effects that may develop at a later date.
Outcomes {12}
Primary outcome
The primary outcome will be the improvement in
radiological healing of lower body stress fractures by two
Fredericson grades or more, or reduction in grade to
zero, 8 weeks after randomisation. Radiological healing
will be assessed using T1 and fluid sensitive (fat
suppressed T2W or short tau inversion recovery) MRI
sequences and the Fredericson grading system (39, 40).
All MRI scans will be assessed independently by two
musculoskeletal consultant radiologists blind to the
randomisation outcome. Assessors will be notified of
any between-assessor grading discrepancies and will be
asked to agree a consensus grade.
Secondary outcomes
Time to radiological healing Radiological healing will
be assessed at weeks 8, 10, 12, 14, 16, 20 and 24 by
MRI, with a Fredericson grade zero classified as
healed [39, 40]. The time from randomisation to
radiological healing will be analysed. No further MRI
scans will be necessary when fractures have healed,
hence the total number of MRI scans a participant
will undergo will vary. All MRI scans will be
conducted and graded using the same methodology
used for the primary outcome.
Time to clinical healing Clinical healing assessments
will commence twice weekly after a participant has been
classified as radiologically healed, using a protocol based
on the index developed by Beck et al. 2012 [41]. A
clinical severity score will be calculated from seven sign
and symptom scores: (i) pain during daily activities; (ii)
night pain; pain when (iii) running and (iv) hopping; and
(v) local tenderness, (vi) pain during percussion, and
(vii) local swelling of soft tissue, each at the site of the
stress fracture. Clinical assessments will cease when a
clinical severity score of zero (i.e. healed) has been
achieved. The time from randomisation to clinical
healing will be analysed.
Time to discharge from Army physical rehabilitation
The time from randomisation to the initial decision to
discharge from Army physical rehabilitation will be
obtained from participants’ Army medical records. A
review by an exercise rehabilitation instructor,
physiotherapist and general practitioner will determine
when a recruit will be discharged from physical
rehabilitation and is, therefore, considered to be fully fit
and ready to return to training.
Pain symptoms Participants will rate the level of pain
they are feeling on a visual analogue scale once-a-week for
the duration of their participation in the study [42, 43].
Pain scores will be analysed as a change from baseline.
Health-related quality of life The Short Form (36)
Health Survey (SF-36) will be completed by participants
at baseline and every 4 weeks for the duration of their
participation in the study to assess their health-related
quality of life [44, 45]. The SF-36 is a self-administered
36-item questionnaire that measures health-related qual-
ity of life in eight domains (vitality, physical functioning,
bodily pain, general health perceptions, physical role
functioning, emotional role functioning, social role func-
tioning, and mental health). Each domain is scored from
0 to 100 (lowest to highest level). Physical and mental
summary scores will be obtained by aggregating scores
across domains and analysed as a change from baseline.
Adverse events Any unfavourable and unintended sign,
symptom or illness that develops or worsens during an
individual’s participation in the study, and for 4 weeks
afterwards, will be recorded and classified as an adverse
event (see the “Adverse event reporting and harms {22}”
section).
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Exploratory outcomes
Blood and urine biochemistry Blood and urine samples
will be collected at baseline and weeks 4, 8, 12 and
16. Where a fracture remains unhealed at week 16,
additional blood and urine samples will be collected
at weeks 20 and 24. Venous blood samples will be
collected from an antecubital vein. The NHS
institution laboratory will analyse blood and urine
samples for safety (Table 1). Aliquots of serum,
plasma and urine will be stored at − 80 °C, before
being defrosted prior to research analyses (Table 1).
Analytes will be analysed as a change from baseline.
All blood and urine biochemical analyses will be
completed by technicians blind to the randomisation
outcome.
Slight and transient elevations of serum calcium
concentration are normal following the injection of
teriparatide. It takes 4–6 h for serum calcium to reach
Cmax and 16–24 h to return to baseline after each dose
[24]. Therefore, blood samples will be collected at least
16 h after a participant’s most recent teriparatide
injection. Where their regular dosing regimen means
treatment would be interrupted to comply with this, the
time of their last dose will be recorded. In the event of a
hypercalcemia result, a trough measurement will be
made within 7 days, before any dose modifications or
discontinuations are made. Randomisation will be
permitted prior to the receipt of baseline plasma
parathyroid hormone concentration. However, in the
unlikely event of a participant presenting with a plasma
parathyroid hormone concentration outside the adult
reference range, they will be called back for review and
instructed to stop injecting teriparatide.
Bone density and morphology Bone density will be
assessed at the lumbar spine and hips by dual-energy X-
ray absorptiometry (DXA) at baseline and week 16
(Lunar iDXA, GE Healthcare, Buckinghamshire, UK).
Bone density and morphology will be measured by per-
ipheral quantitative computed tomography (pQCT)
scans of the diaphyseal tibia (XCT2000L, Stratec, Pforz-
heim, Germany), and high-resolution pQCT (HR-pQCT)
scans of the metaphyseal tibia and radius (Xtreme CTII,
Scanco Medical, Bruttisellen, Switzerland) at baseline
and week 16, and week 24 where a fracture remains un-
healed at week 16. Bone density and morphology will be
analysed as a change from baseline. The non-dominant
arm and non-fractured, non-dominant leg will be
scanned where possible. A random sample of analysed
images (≥ 10%) will be reviewed at the end of the study
by an independent assessor blind to the randomisation
outcome.
Physical activity levels A wrist-mounted tri-axial accel-
erometer will be worn by a subgroup of participants for
the duration of their participation in the study to assess
their physical activity levels. A minimum of 10 partici-
pants in each of the control and intervention arms will
wear an accelerometer.
Long-term future fracture rate Participants’ Army
medical records will be reviewed for 5 years after their
final study visit to record any subsequent bone injuries
and fractures.
Confounding variables Participants’ alcohol consumption
and smoking habits (confounding variables for skeletal
health [46]) will be recorded at baseline and every 4
weeks for the duration of their participation in the
study. Participants’ physical fitness will be recorded
by accessing their Army fitness records.
Participant timeline {13}
A summary schedule of study enrolment, interventions
and assessments is given in Fig. 2.
Sample size {14}
A total sample size of 136 participants will be required (68
participants per trial arm, prior to accounting for drop-
out), based on the primary outcome of an improvement in
radiological healing by two Fredericson grades or more, or
reduction to grade zero, 8 weeks after randomisation. The
sample size was determined using data from Almirol and
colleagues’ (2016) 8 week randomised controlled trial in
adults aged 21–45 years with recent lower-extremity stress
fractures (35). Almirol et al. (2016) reported 67% of partic-
ipants who received teriparatide achieved a two grades or
more improvement in healing or reduction to grade zero
(i.e. ‘success’); compared with 43% of participants in the
placebo group [35]. Assuming a 20% drop-out rate during
the first 8 weeks of the present study, 108 participants (54
participants per trial arm) will complete an MRI scan at
week 8; thereby providing 80% statistical power to detect a
between group difference (two-sided test, significance
level of 5%), if the ‘success’ rate is ≥ 71% in the interven-
tion arm (chi-squared test with continuity adjustment).
This equates to an odds ratio of 3.23 or a relative increase
in healing of approximately 65%.
Recruitment {15}
Potential participants with single or multiple lower body
stress fractures diagnosed by MRI will be identified by
physiotherapists and general practitioners at Infantry
Training Centre, Catterick. Potential participants will be
given a participant information sheet and will be invited
to meet investigators for a detailed explanation of the
study as soon as practicable. The planned recruitment
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period (18 months) has been calculated using the most
recent data on rates of lower body stress fracture
injuries during Infantry training to enable the study to
reach the target sample size.
Assignment of interventions: Allocation
Sequence generation {16a}
Eligible participants who provide written, informed
consent will be randomised on a 1:1 basis to one of two
trial arms using a web-based randomisation process
(REDCap). Allocation will be made after eligibility has
been confirmed. This process will use blocked random-
isation with block lengths of 2–6 in random order. Allo-
cation will be stratified by vitamin D status, measured at
baseline (serum 25-hydroxyvitamin D < 30 nmol/L, defi-
cient; or ≥ 30 nmol/L, not deficient), and whether the
participant has single or multiple lower body stress frac-
ture sites.
Concealment mechanism {16b}
Randomisation will be performed centrally using a web-
based randomisation process (REDCap).
Fig. 2 Schedule of study enrolment, interventions and assessments. 1Intervention and assessments to continue after week 16 only where
fractures are unhealed at week 16; 2Serum 25-hydroxyvitamin D < 30 nmol/L, deficient; ≥30 nmol/L, not deficient; 3Daily subcutaneous injection
(20 μg/day); 4Magnetic resonance imaging (MRI) scans to cease when fracture is radiologically healed; 5Clinical assessments twice weekly after
fracture is radiologically healed, and to cease when fracture is clinically healed; 6Weekly visual analogue scale; 7Short Form (36) Health Survey;
8Adverse events recorded for 4 weeks after participant’s final study visit (i.e. until weeks 20 or 28). 9Safety and research blood biochemistry;
10Safety and research urine biochemistry; 11Dual-energy X-ray absorptiometry (DXA) scan of the lumbar spine and hips (allocation and week 16
only); peripheral quantitative computed tomography (pQCT) scan of the diaphyseal tibia; and high-resolution pQCT (HR-pQCT) scan of the
metaphyseal tibia and radius; 12Accelerometer worn 24 h/day and replaced four-weekly; 13Review of Army medical records for 5 years after
participant’s final study visit; 14Columbia-Suicide Severity Scale for all at allocation, and four-weekly for participants allocated to the intervention
arm; 15Review of Army fitness records; 16Pregnancy test for all at allocation, week 16 and 24, and four-weekly for participants allocated to the
intervention arm
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Implementation {16c}
The randomisation schedule will be generated by
Norwich Clinical Trials Unit (NCTU). Eligible
participants will be enrolled by an appropriately trained
clinician or delegated member of staff at the NHS
institution who will randomise participants using the
web-based study database.
Assignment of interventions: Blinding
Who will be blinded {17a}
All MRI scans (primary outcome) will be assessed by
two musculoskeletal consultant radiologists; all blood
and urine biochemical analyses will be completed by
technicians; and bone density and morphology images
will be reviewed at the end of the study by an
independent assessor, all of whom will be blind to the
randomisation outcome.
Procedure for unblinding if needed {17b}
This is an open label design and neither participants nor
investigators will be blind to the randomisation
outcome. There will be no expected circumstances
where the radiologists, technicians or bone density and
morphology image assessor will need to be aware of a
participant’s allocated intervention.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Investigators will be trained centrally in the use of data
collection instruments, laboratory equipment,
questionnaires, case report forms, and data entry onto a
central database. Investigators will follow standard
operating procedures and working instructions to help
ensure valid and reliable data are collected.
Standardising these processes will enhance data quality
and reduce bias by detecting and reducing the quantity
of missing or incomplete data, inaccuracies, and
excessive variability in measurements [47]. Screening
and eligibility data will be collected by investigators
using case report forms prior to allocation (Fig. 2).
Radiological healing will be assessed by two
musculoskeletal consultant radiologists blind to the
randomisation outcome, using Fredericson grading of
MRI [39, 40], and will be recorded using case report
forms. Clinical healing will be assessed by investigators
using a standardised protocol and case report form [41].
The date of the initial decision to discharge from Army
physical rehabilitation will be obtained from participants’
Army medical records and recorded by investigators
using case report forms. The SF-36 questionnaire will be
completed by participants to assess health-related quality
of life [44, 45], and investigators will verbally ask partici-
pants the questions in the C-SSRS questionnaire to as-
sess depression. Participants will record their pain on a
visual analogue scale [42, 43]. Investigators will ask par-
ticipants to report adverse events and their use of con-
comitant medications, which will be recorded using case
report forms. Participants’ alcohol consumption and
smoking habits will be recorded by investigators com-
pleting case report forms. In accordance with standard
operating procedures, physical activity levels will be
assessed using accelerometers (in a minimum of 10 par-
ticipants in each of the control and intervention arms),
venous blood samples will be collected by investigators,
urine samples will be collected by participants, and
blood and urine biochemistry will be analysed by techni-
cians blind to the randomisation outcome (Table 1).
Pregnancy tests will be conducted according to standard
operating procedures. Bone density and morphology will
be assessed by investigators using DXA, pQCT and HR-
pQCT, according to standard operating procedures, with
a random sample of analysed images (≥ 10%) reviewed
at the end of the study by an independent assessor blind
to the randomisation outcome. Physical fitness will be
recorded by investigators accessing participants’ Army
fitness records. Army medical records will be reviewed
by investigators to record any subsequent bone injuries
and fractures.
Plans to promote participant retention and complete
follow-up {18b}
Investigators will maintain regular contact with
participants throughout their participation in the trial to
offer support as required. Participants will be asked for
their preference with regards to the form this will take
(i.e. telephone or video calls, text messages, emails, face-
to-face consultations). All participants will meet with in-
vestigators a minimum of every 4 weeks. Participants
who remain onsite at Infantry Training Centre, Catterick
will meet with investigators as frequently as every day.
Study visits will be scheduled to avoid disruption to each
participant’s rehabilitation programme, with the aim to
incorporate the trial into routine life within their bar-
racks. Participants who discontinue or deviate from their
allocated intervention protocol will remain in the trial
for all follow-up visits, provided they are willing. For
participants who withdraw or are withdrawn from the
study, all data collected up to the date of withdrawal will
be retained for use in the study. The reason for with-
drawal, if given, and loss to follow-up will be recorded.
Data management {19}
Each participant will be given a unique trial participant
identification number (PIN). Data will be recorded on
paper case report forms first and will then be entered
under the participant’s PIN onto a central database
(REDCap) stored on secure servers at the University of
East Anglia. Data will be recorded and entered by
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investigators (trained for data entry) at Infantry Training
Centre, Catterick and the NHS institution. The database
will be accessed using unique, individually assigned
usernames and passwords, with access limited to study
investigators, the Trial Team at NCTU, and external
regulators if required. The type of activity a user may
undertake will be controlled by the privileges associated
with their personal password-protected account and
REDCap data access groups. A full audit trail of data
changes will be maintained prior to the data lock. Data
integrity will be ensured by using referential data rules,
and valid value, range, and consistency checks. Staff at
NCTU will review case report form data for errors and
missing key data points. The trial database will also be
programmed to generate reports on errors and error
rates.
Servers at the University of East Anglia are protected
by firewalls and are patched and maintained according
to best practice. The location of the servers is protected
physically and environmentally in accordance with the
University of East Anglia’s General Information Security
Policy 3 (Physical and environmental security). The
database and associated code have been developed by
NCTU Data Management, in conjunction with the Trial
Team. The database software provides several features
to help maintain data quality, including maintaining an
audit trail, allowing custom validations on all data,
allowing users to raise data query requests, and search
facilities to identify validation failure/missing data. After
completion of the trial, the database will be retained on
University of East Anglia servers for on-going analysis of
secondary and exploratory outcomes.
Confidentiality {27}
Paper copies of personal data will be kept at trial sites in
a secure location with restricted access. Following
consent, identifiable data will be kept on the trial
database to allow investigators to contact participants in
order to arrange study visits. Only authorised Trial
Team members will have password access to this part of
the database, and this information will be destroyed one
month after closure of the study. The confidentiality of
participants’ personal data will be ensured by not
recording participant names on case report forms and
limiting access to personal information held on the
NCTU database. The PIN will be the primary identifier
for a participant, with secondary identifiers of their date
of birth and initials. The participant’s consent form will
carry their name and signature and will not be kept with
any additional participant data. The identification,
screening and enrolment logs, linking participant
identifiable data to the pseudoanonymised PIN, will be
held locally and securely by trial sites. Trial records will
be archived by Norfolk and Norwich University
Hospitals NHS Foundation Trust (NNUH) as per
current regulatory requirements. Data will be handled in
accordance with provisions of the General Data
Protection Regulation (EU) 2016/679 and the Data
Protection Act 2018.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
No specimens will be collected for genetic or molecular
analysis.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
A full statistical analysis plan (SAP) will be developed by
the Trial Statistician and Chief Investigator before the
final data lock and will be submitted to the independent
Data Monitoring Committee (DMC) and Trial Steering
Committee (TSC) for approval [48]. The primary
efficacy analysis will be based on the intention-to-treat
principle in which all participants will be analysed ac-
cording to the trial arm to which they were allocated, re-
gardless of compliance. The primary outcome
(radiological healing by two Fredericson grades or more,
or reduction in grade to zero, 8 weeks after randomisa-
tion) will be analysed using a logistic regression model.
This model will include the baseline stratification vari-
ables (vitamin D status and single or multiple lower
body stress fractures); anatomical site of fracture; base-
line MRI grade; allocated trial arm; and any other base-
line prognostic variables pre-specified in the SAP. The
estimate of efficacy will be the between group difference
from the analytical model, calculated with 95% confi-
dence intervals and with statistical significance set at the
5% level (two-sided). Secondary outcomes will be ana-
lysed in an analogous manner, i.e. using appropriate stat-
istical models with stratification variables, additional
specific prognostic variables (including the baseline value
of the outcome where available) and allocated trial arm.
A secondary analysis of MRI grading at each time point
using a logistic regression model with a generalised esti-
mating equation approach to parameter estimation and
a specified auto-regressive correlation structure, i.e. to
allow for the correlation in outcome between timepoints,
will also be completed.
Interim analyses {21b}
No formal interim efficacy analyses are planned.
Recruitment and withdrawal rates will be reviewed
during the trial on an ongoing basis. The independent
DMC will review information on the progress and
accruing data of the trial (e.g. recruitment rates, data
quality, adherence to protocol treatment and follow-up,
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main study outcomes, and safety data) and provide ad-
vice on the conduct of the trial to the independent TSC.
The TSC, on recommendation from the DMC, will have
the ability to propose protocol changes, modify target re-
cruitment, halt recruitment within a subgroup, and in
exceptional circumstances prematurely terminate the
trial. The Ministry of Defence will also have the ability
to terminate the trial if, for example, it fails to deliver
the required recruitment rate.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
At present, no sub-group analyses are planned. Any that
arise will be pre-specified in the SAP.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
The primary efficacy analysis will be based on the
intention-to-treat principle in which all participants will
be analysed according to the trial arm to which they
were allocated, regardless of compliance. A secondary,
sensitivity efficacy analysis will be carried out using im-
putation of missing data, if deemed appropriate based
upon likely mechanism of ‘missingness’ and the degree
of missing data. This will be specified in the SAP. The
quantity of missing data will be reported, and a compari-
son made of those included in the primary analysis and
those excluded due to missing data (either missing the
primary outcome or baseline data for the analytical
model).
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
Requests for access to the full protocol, data, and
statistical code will be considered, and approved in
writing where appropriate, after formal application to
the TMG or TSC. After completion of the trial,
applications can be made to NCTU.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
Trial Team
The Chief Investigator, Trial Manager and the NCTU
will be responsible for the day-to-day running of the trial
and implementing trial-specific processes. They will
work together with representatives from the Ministry of
Defence as the Trial Team.
Trial Management Group
The TMG (Sponsor Representative, Chief Investigator,
and Ministry of Defence, NCTU and University of East
Anglia co-investigators) will assist with developing the
design, coordination and strategic management of the
trial.
Trial Steering Committee
The TSC will be the independent group responsible for
oversight of the trial and ensuring it is performed
according to Good Clinical Practice in order to
safeguard participants. The TSC will provide advice to
the Chief Investigator, NCTU, the funder (Ministry of
Defence) and Sponsor (NNUH) on all aspects of the trial
through its independent chair.
Composition of the data monitoring committee, its role
and reporting structure {21a}
Data Monitoring Committee
The DMC will be independent from the Sponsor and
competing interests and will be the only oversight body
that has access to accumulating comparative data. The
DMC will be responsible for safeguarding the interests
of participants, monitoring the accumulating data, and
making recommendations to the TSC on whether the
trial should continue as planned. The DMC will
consider data in accordance with the SAP and will
advise the TSC through its chair.
Adverse event reporting and harms {22}
The definitions of harm according to the European
Union directive 2001/20/EC Article 2 and detailed
guidance laid out in 2011/C172/01, based on the
principles of the International Council for
Harmonisation for Good Clinical Practice, will be
applied in the RETURN trial. All adverse events and
reactions will be assessed for seriousness, causality,
severity and expectedness and will be reported to the
relevant regulatory bodies. Any unfavourable and
unintended sign, symptom or illness that develops or
worsens during the study (and for 4 weeks after a
participant’s final visit) will be classified as an adverse
event, whether or not it was considered to be related to
the study intervention. Adverse events will include
unwanted side effects, sensitivity reactions, abnormal
laboratory results, injuries and inter-current illnesses,
and may be expected or unexpected. All events will be
followed until resolution. There will be no exempted ad-
verse events in this trial. A notifiable event will be grade
3 (or higher) haematological toxicity (according to Com-
mon Terminology Criteria for Adverse Events v5.0),
identified in blood tests whilst a participant is taking
trial medication. The TMG will review line listings of
cumulative serious adverse events. Any concerns about
potential emerging toxicity will be escalated to the inde-
pendent DMC. The DMC will review safety data includ-
ing reported frequencies of non-serious adverse events,
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serious adverse reactions and suspected unexpected ser-
ious adverse reactions.
Frequency and plans for auditing trial conduct {23}
The frequency, type and intensity of routine and
triggered on-site monitoring will be detailed in the qual-
ity management and monitoring plan. On-site visits will
be arranged every 6 months, or more frequently if con-
cerns are raised by the Trial Team, Sponsor or TMG.
Site monitoring will be performed by a member of
NCTU delegated to perform monitoring tasks. The qual-
ity management and monitoring plan will also detail the
procedures for review and sign-off of monitoring
reports.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Amendments to the protocol will be agreed by the TMG
and submitted to MODREC for approval. Amendments
will not be implemented until approvals from the
Medicines and Healthcare products Regulatory Agency
(MHRA) and Health Research Authority have also been
received, and research sites have confirmed their
acceptance with NCTU. The public study record on
ClinicalTrials.gov will be updated with protocol
amendments.
Dissemination plans {31a}
The results of the trial will be disseminated regardless of
the direction of effect and will be reported according to
the Consolidated Standards of Reporting Trials
statement [49]. Results of the trial will be disseminated
by publication in appropriate journals and conference
presentations. Permission to publish from the Ministry
of Defence will be required prior to publication. A lay
summary of the trial results will be given to all
participants at the end of the study.
Discussion
The RETURN trial will be the first study to investigate
the effect of teriparatide on lower body stress fracture
healing in young, otherwise healthy men and women.
The use of MRI and blinded review using the validated
Fredericson stress fracture classification system will
enable radiological healing to be examined as the
primary and as a secondary study outcome [39, 40]. As
the gold standard for assessment of bone stress injury,
MRI has been shown to be the most sensitive and
specific imaging test for diagnosing lower body stress
fractures [50] and will, therefore, allow injury severity
and recovery progress to be closely monitored. In
addition, MRI is non-invasive and will not expose partic-
ipants to ionising radiation, in contrast to conventional
radiology, nuclear scintigraphy and computed tomog-
raphy [50]. The protocol of two-weekly MRI scans from
weeks 8–16, and four-weekly from weeks 16–24, until
fracture healing, will enable the time to radiological
healing to be captured with greater accuracy than in pre-
viously published literature [27–30, 32, 33, 35]. By using
MRI to assess healing, the efficacy of teriparatide will be
examined using an outcome that participants and re-
viewers are unable to manipulate.
The recovery of participants’ physical function and
health will be assessed using a variety of methods. Using
a clinical severity score to assess clinical healing once a
fracture is radiologically healed will enable a
standardised assessment of physical function to be made
[41]. In addition, the time to discharge from physical
rehabilitation will provide a measure of physical function
and readiness to return to training. The time to
discharge from physical rehabilitation will be affected by
confounding variables e.g. (i) the physical demands of
the training course the participant is re-joining, deter-
mined by the week of training at the time of injury, and
the physical intensity of their regiment’s training
programme; and (ii) the participant’s compliance to, and
engagement with, their rehabilitation programme. Al-
though reliant on self-report, the pain visual analogue
scale and SF-36 are relatively easy to complete and will
add minimal additional burden to participants. The vis-
ual analogue scale has been shown to be a valid and reli-
able tool to assess pain [42, 43] and will be interpreted
alongside the participant’s record of analgesic use. The
widely used SF-36 will provide a valid and reliable meas-
ure of health-related quality of life, functional health and
wellbeing [44, 45]. The inclusion of assessments of blood
and urine biochemistry; bone density and morphology;
and physical activity levels will provide an insight into
the mechanisms underlying the hypothesised beneficial
effect of teriparatide on stress fracture healing. Partici-
pants’ alcohol consumption, smoking habits and physical
fitness (confounding factors for skeletal health [46]) will
be recorded so the possible effect of these variables on
study outcomes can be analysed.
One of the challenges associated with the collection of
the outcome measures is the burden placed on
participants. To mitigate trial burden, study visits will be
scheduled to avoid disruption to participants’ Army
training and physical rehabilitation programme, and
with transport provided as required. In addition, the
week 4 study visit, when many participants are expected
to be on sick leave, will be completed at the participant’s
home if required. The requirement for participants to be
undergoing Phase One or Two Army training, and focus
on Infantry training in particular, means a standardised
rehabilitation programme will be followed by all
participants. This will enable the efficacy of teriparatide
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to be examined with greater control over confounding
variables, such as variation in rehabilitation programmes
and access to facilities, than would likely be possible
among athletic or civilian cohorts.
Safety
One safety concern associated with teriparatide during
its development was the possible association with
osteosarcoma, due to a preclinical animal study
reporting a dose-dependent increase in the incidence of
osteosarcoma and some other rare bone tumours in one
breed of rat, treated with near life time, high doses of
teriparatide [25]. This finding was not observed in subse-
quent animal studies with other animal models or breeds
of rat, and treatment with teriparatide in humans has
been demonstrated to be safe, with no association be-
tween teriparatide and osteosarcoma observed since sur-
veillance studies commenced in 2003 and 2009 [24–26].
The maximum total duration of treatment with teripara-
tide was increased from 18 to 24 months by the Euro-
pean Medicines Agency and US Food and Drug
Administration based on safety data and post-marketing
experience [51, 52].
For safety, participants’ blood and urine samples,
collected at baseline and every 4 weeks throughout the
study, will be analysed to ensure they are within adult
reference ranges (analytes listed in Table 1).
Hypercalcaemia and hypercholesterolaemia have been
reported in individuals treated with teriparatide [24];
hence, serum calcium and total cholesterol will be
monitored throughout the study. Teriparatide may cause
small increases in urinary calcium excretion [24]; thus,
participants’ urine calcium will be monitored.
Participants will be expected to be otherwise healthy
because in order to be undergoing Army training, they
will have recently passed a physician screened medical
assessment.
Teriparatide should not be given to individuals with
open epiphyses [24]; thus, potential participants who
present with open epiphyses in their diagnostic MRI
scan will be excluded from participating. Signs of
depression will be monitored using the C-SSRS because
depression is a possible side effect of treatment with teri-
paratide [24]. Women will require a negative serum
pregnancy test result to be eligible to participate and
must agree to use of a highly effective form of contra-
ception (failure rate < 1% per year, e.g. combined
oestrogen and progestogen, or progestogen-only hormo-
nal contraception, or intrauterine device) because teri-
paratide is contraindicated for use during pregnancy
[24]. Treatment with teriparatide will be discontinued
for participants who become depressed or pregnant. A
negative urine pregnancy test result will be required
prior to teriparatide re-dispensing. Dual-energy X-ray
absorptiometry, pQCT, and HR-pQCT scans will expose
participants to ionising radiation, however, the total ra-
diation exposure for each participant will be relatively
low, categorised as minor risk (0.1–1 mSv; Category IIa)
[53]. A negative pregnancy test result will be required
before DXA, pQCT, and HR-pQCT scans to avoid ex-
posing pregnant women to ionising radiation.
Protocol amendments
The following amendments were approved by
MODREC, resulting in the current study protocol
described here (version 1.6). In June 2019, during the
planning stage, the study was changed from a double
blind, placebo-controlled trial to an open label design,
with usual Army standard care as the control arm. The
principal reason for this change was the rejection of re-
turn to training as a potential primary endpoint, since
readiness to return to training was considered too sub-
jective, and the subsequent choice of an objective pri-
mary endpoint of improvement in radiological healing
assessed by MRI. There is no known biological mechan-
ism by which participants can influence radiological
measures of stress fracture healing, therefore, this ob-
jective endpoint lends itself to an open label design. A
second reason was the continued unavailability of a suit-
able placebo. An open label design has the added bene-
fits of reducing the burden on control arm participants
by removing the requirement for them to administer
daily injections of placebo for 24 weeks, and avoids the
possible ethical implications of requiring them to do so;
it may also increase compliance within the intervention
arm since participants will know they are receiving ac-
tive drug. The practical issue of adherence to the injec-
tion regime by military recruits, knowing they are
receiving drug, is important for the future roll out of any
treatment regime. Additional amendments were the
protocol for calcium and vitamin D supplementation
where serum calcium is < 2 mmol/L; the requirement for
participants to be prescribed vitamin D as part of their
standard care (if vitamin D deficient); MRI scans at
weeks 20 and 24, where a fracture remains unhealed at
week 16; a subgroup of participants to wear accelerome-
ters to assess their physical activity levels; and clarifica-
tion regarding randomisation whereby allocation will be
stratified by vitamin D status and single or multiple
lower body stress fracture sites.
In August 2019, during the study planning stage, the
exclusion criteria were modified to exclude potential
participants with depression, indicated by the C-SSRS,
and to add the provision that participants who exhibit
signs of depression (as indicated by the C-SSRS) will
have their teriparatide treatment discontinued.
In April 2020, an inclusion criterion was reworded
from ‘lower limb stress fracture’ to ‘lower body stress
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fracture’, where lower body includes the pelvic girdle,
sacrum, coccyx and lower limb. The pQCT scanning of
the diaphyseal tibia was added because the available HR-
pQCT scanner (Xtreme CTII, Scanco Medical) is unable
to analyse this anatomical site. As potential confounding
variables, the collection of participants’ alcohol con-
sumption, smoking habits and physical fitness were
added to the protocol. Analysis of butyrate was added as
an exploratory outcome due to emerging evidence that
it may influence parathyroid hormone-dependent bone
formation. Butyrate produced by gut luminal microbiota
has a role in triggering regulatory pathways which are
required for the anabolic action of parathyroid hormone
in bone [54]. Study MRI results are considered by the re-
habilitation staff to constitute additional clinical infor-
mation relevant to participants’ treatment and discharge
from rehabilitation. Therefore, once the decision to dis-
charge a participant from rehabilitation and to return to
training has been made and recorded, it was clarified
that the most recent MRI scan results will be released to
the rehabilitation staff who will then be at liberty to
proceed or to revise their decision as they see fit, before
communicating the outcome to the participant. This
change was designed to fulfil a duty of care to partici-
pants, but without interfering with usual Army standard
care or the initial decision to discharge from rehabilita-
tion (a secondary outcome).
In October 2020, in response to the COVID-19 pan-
demic, the option for some NHS site study visits and
procedures to be completed remotely (via telephone or
video call) or at Infantry Training Centre, Catterick with
NHS oversight, were added to the protocol. These in-
clude the option for adverse event and concomitant
medication checks to be completed by NHS staff via
telephone or video calls; and the option for blood and
urine samples to be collected at Infantry Training
Centre, Catterick with NHS oversight. Allocation, con-
firmation of eligibility and obtaining informed consent
will remain the responsibility of the NHS institution, but
can be completed by telephone or video call. If access to
the NHS hospital is restricted or MRI services are un-
available, MRI scans can be completed using a scanner
local to Catterick instead of those at NHS sites. The ob-
jectives behind these COVID-19 changes were to protect
participants and investigators from SARS-CoV-2 and the
development of COVID-19, by eliminating as far as pos-
sible the need to visit NHS hospitals and by following
local and national government restrictions on social dis-
tancing and travel; to remove the greatest burden pos-
sible from NHS staff, in line with MHRA and National
Institute for Health Research guidance (published 21st
May 2020 [55]); and to keep the trial open, if safe to do
so, in the event of future virus outbreaks. It was clarified
that women will require a negative pregnancy test result
before teriparatide dispensing, and before DXA, pQCT,
and HR-pQCT scans. A formal review of the recruit-
ment rate and feasibility of the study by the TMG (ori-
ginally scheduled to be evaluated 6 months after the trial
opening) will take place 6 months after the trial reopen-
ing following the pause in recruitment caused by the
COVID-19 pandemic.
Perspectives and future directions
If the study finds teriparatide to be effective for
accelerating stress fracture healing, military recruits
injured with lower body stress fractures could be treated
with teriparatide as part of their standard care, subject
to balance of investment and health economics analysis,
approval by the Army Drugs and Therapeutics
Committee, and incorporation into the Army stress
fracture treatment protocol. The long-term future frac-
ture rate recorded in the study will provide an insight
into the fracture preventative potential of teriparatide in
young, otherwise healthy adults. Investigating the effi-
cacy of teriparatide administered using an alternative de-
livery route that would eliminate the need for daily
subcutaneous injections would be of interest. Oral dos-
ing is potentially a more convenient method of adminis-
tering teriparatide [56]; however, it is currently being
investigated in early phase clinical trials and was not
available for the present study.
Trial status
The current protocol is version 1.6 (10th September
2020). The first participant was recruited on 29th
January 2020. Recruitment was paused on 24th March
2020 due to the COVID-19 pandemic. No participants
had reached the week 8 primary endpoint by this date.
The TMG made the decision on 24th March 2020 that
no further in person assessments would be undertaken,
but where possible participants would complete second-
ary endpoint assessments by telephone, up to the week 8
timepoint, before being withdrawn from the study. The
first participant after the pause in recruitment caused by
the COVID-19 pandemic was recruited on 2nd October
2020. Recruitment will continue until approximately
April 2022. The incidence of stress fractures and subse-
quent recruitment has been lower than anticipated due
to the COVID-19 pandemic. Therefore, the TMG intend
to obtain approval to expand recruitment from Army re-
cruits to the wider UK Armed Forces so the required re-
cruitment rate can be met.
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